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Abstract 
 
Background: Patients with kidney disease are more likely to develop atrial fibrillation (AF) than 
individuals with normal renal function, and more likely to suffer ischemic stroke (IS) 
/thromboembolism (TE). We investigated the relationship of kidney function evolution to IS/TE, 
mortality and bleeding in AF patients. 
Methods: In a cohort of 8962 AF patients, 2653 had serum creatinine data, with 10894 patient-
years of follow-up. Patients were stratified into quartiles of estimated glomerular filtration rate 
(eGFR) evolution (in ml/min/1.73 m
2
/year). 
Results: Rates of events (IS/TE, bleeding, mortality) increased with worsening eGFR by quartiles. 
The risk of events was particularly increased when patients in the 4th quartile were compared to 
others. Renal impairment per se was not an independent predictor of IS/TE but was an independent 
predictor of bleeding, whilst eGFR worsening was an independent predictor both for IS/TE (Hazard 
Ratio [HR] 1.573, 95%CI 1.160-2.134 for patients in the last quartile) and for bleeding events (HR 
1.543, 95%CI 1.157-2.004). Worsening eGFR did not improve the predictive ability of the 
CHA2DS2VASc and HAS-BLED scores for identifying a higher risk of IS/TE or bleeding events, 
respectively. When the benefit of IS reduction was balanced against the increased risk of bleeding 
events, the net clinical benefit was positive in favor of OAC use (vs non-use) in patients with 
worsening eGFR. 
Conclusions: Rates of IS/TE, mortality and bleeding increased with worsening eGFR >4.81 
ml/min/1.73 m
2
. Worsening eGFR was an independent predictor of IS/TE and of bleeding, and a 
better predictor of IS/TE than renal impairment in AF.  
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Introduction 
 
Chronic kidney disease (CKD) and atrial fibrillation (AF) are both independently associated with 
poor cardiovascular outcomes and all-cause mortality, presenting a growing global burden of 
disease
1-10
. Individuals with CKD are more likely to develop AF, ischemic stroke (IS) and 
thromboembolism (TE)
11
 than patients with normal renal function. In a large study of Danish 
individuals with AF, CKD was associated with increased risk of IS/TE and bleeding
12
, confirming 
observations of previous smaller studies
13, 14
. Renal failure is included as a dichotomous variable in 
risk prediction tools for bleeding but is less evident in guideline-recommended risk prediction tools 
for IS/TE
14-17
, and we found that renal impairment and eGFR does not independently improve 
IS/TE risk prediction
1
. In clinical practice, renal function is quantified by the estimated glomerular 
filtration rate (eGFR)
18, 19
. Whilst eGFR was a debated independent predictor of IS/TE in several 
studies with AF patients, some patients are still ‘high risk’ and regular checks on eGFR are 
recommended, especially since mild renal impairment at baseline does not preclude some patients 
deteriorating to severe renal impairment
20
.  
No prior epidemiologic studies have considered the impact of changes in eGFR on long-
term outcomes in individuals with AF. Therefore the balance between risk of IS/TE and bleeding 
has not been quantified by worsening in eGFR in a large ‘real world’ population of individuals with 
AF. This study investigated the relationship of eGFR evolution to IS/TE, mortality and bleeding in 
an AF population, unrestricted by age or comorbidity. 
 
Methods 
 
Between January 2000 and December 2010, 8962 patients seen in the Cardiology department in our 
institution with a diagnosis of AF were identified. 
1, 2
. The regional university hospital of Tours 
serves approximately 400,000 inhabitants and is the only public institution in an area of about 4,000 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
5 
 
km². The information for each patient was extracted from computerized data of hospitalization and 
consultation of our institution. During follow-up, information on outcomes was recorded and we 
defined major bleeding using the Bleeding Academic Research Consortium (BARC) definitions
21
. 
VKA therapy was the only form of OAC used during the study period.  
 
Assessment of renal function 
Renal impairment at baseline was defined as glomerular filtration rate (GFR) of less than 60 
mL/min/1.73m
2
 
22
. Baseline eGFR was recorded at the time of the first record of AF (i.e. index 
date). Creatinine-based GFR estimating equations have greater utility in assessing kidney function 
compared to creatinine measurement alone 
23, 24
. In adults, the most widely-used and validated 
method for estimating GFR from serum creatinine level is the isotope dilution mass spectrometry 
(IDMS)-traceable Modification of Diet in Renal Disease (MDRD) Study equation 
18, 19
. The MDRD 
equation was preferred to the “CKD-Epi” equation25 because there were very few patients age≥75 
years in cohorts used to validate this equation whereas the current study population was unrestricted 
by age. The African population in the present study population was <1% and therefore no 
correction factor for ethnicity was required in the MDRD calculation of eGFR. Patients with 
duration between first and last eGFR calculation <180 days were excluded of the analysis. We then 
estimated change in eGFR by calculating eGFR slope during follow-up, expressed in 
ml/min/1.73m
2
/year and defined as (last eGFR calculation minus first eGFR calculation)/(duration 
between first and last eGFR calculation). For patients a clinical event, last eGFR was the last eGFR 
obtained before the first outcome of interest recorded in this study.  
 
Statistical analysis 
The study population was stratified into quartiles according to eGFR changes (in ml/min/1.73 
m
2
/year). Baseline characteristics were determined in the 4 quartiles, and differences were 
investigated using chi-squared test for categorical covariates and Kruskal-Wallis test for continuous 
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covariates. Cox-proportional hazards analyses were performed to investigate whether renal 
impairment and eGFR evolution were independent predictors of events. The risk associated with 
renal impairment and eGFR evolution were estimated with hazard ratio (HR) in a univariate 
analysis, as well as a sex- and age-adjusted analysis, and a multivariate analysis adjusted for the risk 
factors included in the CHA2DS2-VASc and HAS-BLED scores and antithrombotic therapy.  
 
We assessed the predictive capability of CHA2DS2-VASc and HAS-BLED scores using Harrell’s c-
statistic with 95% CIs as a measure of model performance. The CHA2DS2-VASc and HAS-BLED 
scores were analyzed as categorical risk groups and the effect of adding eGFR worsening as a 
categorical variable (patients in the 4th quartile of eGFR worsening) to the scores was determined. 
The value of adding eGFR worsening as a categorical variable to the established risk scores was 
also evaluated by Net Reclassification Improvement (NRI) and Integrated Discrimination 
Improvement (IDI)
26
.  
Finally, the net clinical benefit (NCB) of treatment was calculated using the method proposed by 
Connolly
27
 which uses a weighted sum of rate differences ΔR = Rate not treated – Rate treated:  
NCB = w1*ΔR ischemic stroke + w2*ΔR ICH + w3*ΔR major bleeding + w4*ΔR MI,  
where major bleeding refers to major extracranial bleeding, ICH=intracranial hemorrhage, MI= 
myocardial infarction and weights w1=1, w2=3.08, w3=0.67, w4=0.95. 
The NCB is used by clinicians as a method of balancing risk of ischemic stroke and 
thromboembolism, against ICH.  
 
Ethics approval 
This type of study registered as a clinical audit was approved by the review board of the Pole Coeur 
Thorax Vaisseaux from the Trousseau University Hospital on December 7, 2010. Ethical review 
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was therefore not required. Patient consent was not sought. Patient data were utilized only to 
facilitate the cross referencing of data sources and records were otherwise anonymous. The study 
was conducted retrospectively, patients were not involved in its conduct, and there was no impact 
on their care. No extramural funding was used to support this work. The authors are solely 
responsible for the design and conduct of this study, all study analyses, the drafting and editing of 
the paper and its final contents. 
 
Results 
 
Of 8962 individuals with AF seen in the cardiology department, 2653 had several available serum 
creatinine data allowing the eGFR (expressed in ml/min/1.73m
2
) and eGFR evolution (slope of 
eGFR, expressed in ml/min/1.73m
2
/year) to be calculated (Figure 1). The number of samples with 
creatinine level assessment was 12±14 per patient (median 7, interquartile range 4-14).  
 
Baseline characteristics are shown in Table 1. The eGFR at baseline in this population was 65.5 
ml/min/1.73m
2
. Supplemental table 1 shows comparison of baseline characteristics between 
included patients and patients excluded from the analysis, which were relatively similar in terms of 
age and CHA2DS2-VASc and HAS-BLED scores, although included patients more frequently had 
coronary artery disease or heart failure. Quartiles based on eGFR slope determined 4 groups of 
patients with eGFR slope ≥1.56, 1.56 to -1.25, -1.25 to -4.81 and <-4.81 ml/min/1.73m2/year. 
Individuals with decreasing eGFR were older, and more likely to have hypertension, diabetes, 
vascular disease, heart failure, previous bleeding and higher CHA2DS2-VASc and HAS-BLED 
scores. Subjects in the rapid decline group had substantially higher baseline eGFR compared to 
other groups. Decreasing eGFR during follow-up was not associated with differences in rates of 
OAC nor antithrombotic therapies.  
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During a mean follow-up of 1499 days (median 1318, interquartile range 524-2317), the incidence 
rate of IS/TE was 19.6 per 1000 person-years. Rates of all-cause mortality and of major bleeding 
were 26.1 and 27.9 per 1000 person-years, respectively. Rates of all events increased with 
decreasing eGFR, regardless of OAC therapy (table 2).  
 
Figure 2 (top panel) shows the event-free curves for stroke/TE events in the 4 groups based on 
eGFR slope. There was an increased risk of stroke/TE when worsening in eGFR was more marked 
(HR 1.226, 95%CI 1.087-1.381 for each change of quartile) and the risk was markedly increased 
when patients in the 4
th
 quartile were compared to other patients (H  1.803, 95%CI 1.367-2.378). 
Figure 2 (lower panel) shows the event-free curves for bleeding events in the 4 groups based on 
eGFR slope. There was an increased risk of bleeding when worsening in eGFR was more marked 
(HR 1.184, 95%CI 1.071-1.308 for each change of quartile) and the risk was particularly increased 
when patients in the 4th quartile were compared to other patients (HR 1.582, 95%CI 1.245-2.010). 
 
Rates of IS/TE and all-cause mortality were lower in individuals on OAC, compared with those 
individuals not on OAC and the effect was not significantly affected by eGFR worsening quartiles. 
Bleeding rates were higher in individuals on OAC, compared with non-anticoagulated individuals 
and the effect was not significantly affected by eGFR worsening quartiles (table 2). 
 
Table 3 shows the results from regression analyses for IS/TE and bleeding events, respectively. As 
a categorical variable, eGFR worsening (patients in the 4
th
 quartile with eGFR slope <-4.81 
ml/min/1.73m
2
/year) was an independent predictor for IS/TE after adjustment for age, sex, renal 
impairment at baseline, CHA2DS2VASc risk factors and antithrombotic therapy. Renal function 
with eGFR at baseline was a predictor of IS/TE in AF in univariate analysis but was not an 
independent predictor after adjustment for age, sex, and other baseline characteristics. Considering 
bleeding events, eGFR worsening as a categorical variable, was an independent predictor after 
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adjustment for age, sex, renal impairment at baseline, HAS-BLED risk factors and antithrombotic 
therapy. Renal function with eGFR at baseline was also an independent predictor of bleeding after 
adjustment for age, sex, and other baseline characteristics. eGFR worsening as a categorical 
variable was also an independent predictor for total mortality (HR 3.192, 95%CI 2.504-4.069). after 
adjustment for age, sex, renal impairment at baseline, HAS-BLED risk factors and antithrombotic 
therapy. Renal function with eGFR at baseline was also an independent predictor of mortality after 
adjustment for age, sex, and other baseline characteristics (HR 0.980, 95%CI 0.974-0.987).  
 
There was no statistically significant improvement in either the CHA2DS2VASc or HAS-BLED 
scoring systems by the addition of eGFR worsening for identifying the risk of IS/TE and bleeding 
events, respectively. The c-statistic was neither improved when adding eGFR worsening to 
CHA2DS2VASc score (c-statistic 0.558 95%CI 0.534-0.583 for CHA2DS2VASc score, 0.556 
95%0.525-0.587 when adding eGFR worsening in the 4th quartile) nor to HAS-BLED score (c-
statistic 0.547 95%CI 0.523-0.571 for HAS-BLED score, 0.538 95%0.510-0.567 when adding 
eGFR worsening in the 4
th
 quartile). The NRI and IDI were not significantly different by adding 
eGFR worsening to CHA2DS2VASc (NRI -0.092, IDI 0.088, relative IDI 16%). The NRI and IDI 
were neither improved for bleeding by adding eGFR worsening to HAS-BLED (NRI -0.093, IDI 
0.378, relative IDI -66%). 
 
When the benefit of ischemic stroke reduction was balanced against the increased risk of bleeding 
event amongst AF patients with worsening eGFR, the net clinical benefit (NCB) remained positive 
in favor of VKA use. In individuals with eGFR slope >-4.81 ml/min/1.73m
2
/year), NCB was 
1.46(95%CI 0.32-2.67), whilst in those with eGFR slope <-4.81 ml/min/1.73m
2
/year), NCB was 
3.95(95%CI 0.81-7.48).  
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Discussion  
 
In this large series of AF patients, our principal findings are as follows: (i) incidence rates of IS/TE, 
mortality and bleeding increased with worsening eGFR; (ii) worsening eGFR was an independent 
predictor of IS/TE and of bleeding, and a better predictor of IS/TE than renal function at baseline; 
(iii) worsening eGFR did not improve the predictive ability of the CHA2DS2VASc and HAS-BLED 
scores for identifying a higher risk of IS/TE or bleeding events; and (iv) when the benefit of IS 
reduction was balanced against the increased risk of bleeding event, the NCB was positive in favour 
of OAC use in patients with worsening eGFR. 
 
This is the first comprehensive assessment of eGFR evolution in AF patients on IS/TE or bleeding 
risk, and the NCB of antithrombotic therapy. We have previously shown that eGFR does not add 
incremental value to risk prediction in IS/TE
1
. Since renal impairment is commonly associated with 
many of the individual components of CHA2DS2-VASc
 
score, our observation that low eGFR was 
not an independent predictor of IS/TE in AF is unsurprising.  
 
Our observations also confirm the high bleeding risk associated with increasing renal impairment. 
The present study extends prior observations by showing that worsening eGFR was an independent 
predictor for bleeding events. Indeed, the latter may have implications for future risk stratification 
schemes for major bleeding which currently classify (baseline) renal failure as a dichotomous 
variable
14, 16, 17
. Actually, both low eGFR at baseline and falling eGFR over time were combining 
for optimal risk prediction of bleeding events. 
 
The observation that worsening eGFR confers a worse prognosis is perhaps unsurprising since risk 
does not remain static, especially in the elderly AF population with multiple comorbidities and 
polypharmacy. A previous study has shown that approximately 1 in 5 patients with AF demonstrate 
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mean eGFR decrease of >10 ml/min/1.73 m
2
, and that normal or mild renal dysfunction at baseline 
did not exclude the subsequent development of severe renal dysfunction during the follow-up 
period
20
. In another smaller study, an absolute decrease in eGFR ≥25 ml/min/1.73 m2 on MDRD, or 
a relative reduction (≥25%) in eGFR, independently predicted the risk for stroke or death in AF 
patients
28
. Since it is a time dependent variable, eGFR slope is not available at baseline. Several 
years of follow-up (after baseline GFR) were needed to define "GFR slope", which makes our 
concept uneasy to translate into clinical use. Since worsening eGFR is globally a linear function,
29-
31
 the clinician might instead consider a reasonable approach looking at GFR slope during a 
landmark period (e.g. 1 year) and then predict risk using this landmark view. This may have 
implications for regular monitoring of renal function, and use of particular therapies that may be 
associated with less deterioration of renal function
32
. eGFR slope might also refine risk prediction 
during follow-up, as soon as its estimation seems reliable. This may be a new type of tool for risk 
stratification, which has to be used a bit differently than others (available at baseline) for risk 
prediction of future events in AF patients. This would be in line with the opinion that the risks of 
different events are dynamic processes in AF patients and need to be regularly re-evaluated.  
 
Importantly, the cut-off value defining the 4
thquartile in our study (≥5 ml/min/year) has a special 
meaning for nephrologists and corresponds to the so-called "rapid progression of renal disease"
19
. 
Moreover, predictors of rapid progression include (among other parameters) older age, elevated 
blood pressure, hyperglycemia and history of cardiovascular disease
19
. Despite the fact that true 
baseline renal impairment was infrequent in subjects from the present cohort, subjects in the 
4
th
 quartile were indeed older, more often had hypertension, diabetes and history of cardiovascular 
disease, confirming the value of these parameters even in a low renal risk population. Of note, these 
subjects in the rapid decline group had substantially higher baseline eGFR compared to other 
groups. This further emphasizes the point that a single baseline creatinine by itself does not provide 
full information on kidney status for AF patients. It may seem counterintuitive that these patients 
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initially had a better renal function. However, significant worsening in eGFR is probably more 
likely to be seen in patients with relatively preserved eGFR at baseline, whilst patients with lower 
or very low eGFR at baseline are unlikely to have a marked additional decrease in eGFR.  
 
By contrast, some patients had some improvement in eGFR. These patients in the first quartile had 
an initial eGFR which was a bit (but not dramatically) lower than other patients and a follow-up 
duration which was bit lower than in the 2
nd
 and 3
rd
 quartiles. We would thus consider that these 
patients had a stabilization of kidney function on a mid-term follow-up, possibly starting from a 
moderate alteration of kidney function, rather than a marked improvement on a fully normal 
function, which would be difficult to understand. This relatively good clinical response may be part 
of the holistic management of AF, since rate control, rhythm control, management of heart failure 
(whether it is with reduced or preserved ejection fraction), and cardiovascular drugs per se (e.g. 
RAAS blockade) might improve cardiac output and renal perfusion.  
 
Study limitations 
This study is based on a ‘real world’ registry with its inherent limitations, as previously reported1, 2. 
In this retrospective analysis, the slope of eGFR over time may depend on the number of samples 
taken in the individual patients and we did not exclude those with only two draws, in whom slope 
may be less accurate compared to multiple sampling. Patients who experienced severe adverse 
events and early death did not have 2nd measurement of creatinine, and the slope of renal function 
was therefore not assessed. Non-inclusion of patients due to missing data may be related to the fact 
that eGFR may be measured in patients with different comorbidities and the relation with IS/TE 
may be mediated by unmeasured confounders/mediators as opposed to renal deterioration per se. It 
may also be simplistic to assume that renal deterioration is a linear function. In several situations, 
acute kidney injury leads to an abrupt reduction in renal function that does not return to baseline. 
Other biomarkers such as proteinuria and cystatin c values were not available in these patients. 
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Bleeding and thromboembolic events often happen in relation to acute decompensation, which can 
relate to acute renal failure as opposed to CKD progression, and this may not be reflected in overall 
slope. We used a categorical variable analysis for eGFR evolution as this would be more useful in 
terms of being incorporated into a risk prediction score; there was no appreciable difference with 
eGFR slope analyzed as a continuous variable. Despite stratification and adjustment for several risk 
factors, the non-randomized design leaves a risk of residual confounding factors, but the majority of 
randomized trials in AF patients has excluded analyses of the effect of renal function. The study 
population was hospital-based and therefore may not be representative of all patients with AF. The 
study was not ethnically diverse and our findings may not be generalizable to other populations. 
The data regarding OAC use were only regarding baseline therapy and do not reflect any changes in 
prescribed therapy or adherence to therapy. Also, data regarding compliance and the “time in 
therapeutic range” are not available for our study population. Finally, lack of inclusion of patients 
treated with non-vitamin K OACs, which are commonly prescribed and variably cleared by the 
kidneys, is another limitation. 
 
Conclusions 
Worsening renal function (rather than renal impairment) is associated with poor outcomes in 
individuals with AF across the whole range of renal function, as measured by eGFR. Incidence rates 
of IS/TE, mortality and bleeding substantially increased with worsening eGFR. Worsening eGFR 
was an independent predictor of IS/TE and of bleeding, and a better predictor of IS/TE than 
baseline renal impairment. These observations may have implications for future risk prediction 
tools of outcomes in AF as well as future clinical trials. 
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FIGURE LEGENDS 
 
Figure 1. Study population by stage of renal function worsening 
 
Figure 2. Top: Kaplan-Meier estimates of the percentages of patients remaining free of stroke 
and/or thromboembolic events by quartile of renal function worsening. Bottom: Kaplan-Meier 
estimates of the percentages of patients remaining free of major bleeding by quartile of renal 
function worsening. 
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Table 1: Characteristics of patients with atrial fibrillation in relation to degree of renal function 
worsening by quartiles 
 
 GFR slope (in ml/min/1.73 m
2
/year) 
n (%) Q1 
(≥1.56) 
n=661 
Q2 
(1.56 to -
1.25) 
n=662 
Q3 
(-1.25 to -
4.81 ) 
n=666 
Q4 
(<-4.81) 
n=664 
p-value 
 Mean age (SD) 68(14) 68(14) 70(13) 71(14) <0.0001 
 Female 211(31) 241(36) 217(32) 216(32) 0.29 
 Baseline eGFR, ml/min/1.73m² (SD) 60(21) 62(18) 65(17) 71(50) <0.0001 
 Mean follow-up, months (SD) 44(35) 62(38) 57(38) 34(30) <0.0001 
Type of AF     
0.20 
 Paroxysmal 362(55) 377(57) 357(54) 378(57) 
 Permanent 261(39)  232(35) 256(38) 250(38) 
 Persistent 38(6) 53(8) 53(8) 36(5) 
Comorbidities      
 Hypertension 227(34) 231(35) 253(38) 287(43) 0.003 
 Diabetes 82(12)  72(11) 110(17) 139(21) <0.0001 
 Previous stroke 45(7) 57(9) 55(8) 44(7) 0.41 
 Coronary artery disease 208(32) 219(33) 241(36) 260(39) 0.02 
 Vascular disease 147(22) 156(24) 165(25) 200(30) 0.006 
 Heart failure 328(50) 321(49) 375(56) 437(66) <0.0001 
 Renal impairment 43(7) 40(6) 48(7) 63(10) 0.08 
 Liver impairment 3(1) 1(0) 1(0) 4(1) 0.39 
 Dyslipidaemia 129(20) 139(21) 136(20) 145(22) 0.76 
 Smoking 88(13) 84(13) 87(13) 92(14) 0.94 
 Pacemaker/ICD 116(18) 168(25) 194(29) 144(22) <0.0001 
Bleeding risk factors      
 Previous bleeding 32(5) 33(5) 52(8) 67(10) 0.0002 
 Labile INR 13(2) 22(3) 21(3) 19(3) 0.45 
 Anaemia 5(1) 6(1) 9(1) 6(1) 0.71 
 NSAIDs 1(0) 0(0) 4(1) 0(0) 0.04 
 Drugs 124(19) 142(22) 142(21) 144(22) 0.52 
 Cancer 20(3) 15(2) 8(1) 15(2) 0.30 
 Excessive risk of falls 12(2) 4(1) 5(1) 11(2) 0.10 
 Thrombocytopenia 1(0) 0(0) 1(0) 0(0) 0.57 
Antithrombotic agents      
 Vitamin K antagonist 391(64) 380(62) 410(68) 409(67) 0.15 
 Antiplatelet  191(32) 209(35) 199(34) 204(34) 0.80 
 Any antithrombotic  502(84) 506(84) 511(86) 516(85) 0.75 
Other therapies      
 ACEI 225(35) 265(41) 275(42) 298(46) 0.0006 
 Beta-blocker 320(49) 324(49) 360(54) 374(57) 0.008 
 Digoxin 144(22) 154(23) 162(24) 141(21) 0.51 
 Diuretic 38(13) 438(16) 679(25) 96(33) <0.001 
 Antiarrhythmic agent 281(43) 283(43) 274(41) 288(44) 0.87 
 Calcium channel blocker 18(14) 39(21) 25(14) 22(23) 0.11 
CHA2DS2-VASc score (SD) 2.6(1.7) 2.7(1.7) 3.0(1.7) 3.3(1.7) <0.0001 
 Low(score<2 in males, 3 in females) 219(33) 213(32) 158(24) 136(20) <0.0001 
 High(score≥2 in males, 3 in females) 442(67) 449(68) 508(76) 528(80)  
HAS-BLED score 1.4 (1.1) 1.5(1.1) 1.6(1.1) 1.7(1.1) <0.0001 
 Low(score=0) 158(24) 146(22) 123(19) 99(15)  
 Moderate(score=1-2) 408(62) 402(61) 419(63) 423(64) 0.0002 
 High(score≥3) 95(14) 114(17) 123(19) 142(21)  
 
SD: standard deviation; AF: atrial fibrillation; ICD: implantable cardiac defibrillator; INR: international normalised ratio; CHA2DS2-
VASc (1 point for heart failure, hypertension, diabetes, vascular disease, age 65-74, and female gender; 2 points for prior stroke or 
thromboembolism and age ≥75); HAS-BLED (Hypertension, Abnormal renal and/or liver function, Stroke, Bleeding history or 
predisposition, Labile International Normalized Ratio (INR), Elderly (> 65 years).
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Table 2. Event rates (95% confidence interval) per 1000 person years in patients with atrial fibrillation by quartiles of renal function worsening 
 
p-value for 2-sided chi-squared test. TE: thromboembolism. * p-value for interaction. VKA: Vitamin K antagonist. HAS-BLED (Hypertension, Abnormal renal and/or liver 
function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio (INR), Elderly (>  65 years) 
 
 
 
  
 Slope of Estimated glomerular filtration rate(in ml/min/1.73 m
2
/year)  
 Q1 
n=661 
Q2 
n=662 
Q3 
n=666 
Q4 
n=664 
P 
 Events Event rate Events Event rate Events Event rate Events Event rate  
Ischaemic Stroke/TE          
Total 52 2.23(1.70-2.92) 66 2.04(1.60-2.59) 72 2.38(1.89-3.00) 71 4.06(3.21-5.11) 0.0003 
No VKA 18 2.51(1.58-3.94) 27 2.58(1.77-3.74) 21 2.38(1.55-3.62) 17 3.42(2.12-5.43) 0.65 
VKA 31 2.17(1.52-3.07) 38 1.98(1.44-2.71) 45 2.43(1.82-3.25) 46 4.19(3.13-5.57) 0.005 
Relative risk(VKA vs No VKA)   0.86(0.48-1.53)  0.77(0.47-1.25)   1.03(0.62-1.74)   1.24(0.71-2.16)  0.61* 
Ischaemic Stroke/TE/Mortality                
Total 105 4.51(3.72-5.45) 113 3.48(2.90-4.18) 113 3.74(3.11-4.49) 178 10.18(8.77-11.76) <0.0001 
No VKA 46 6.40(4.78-8.49) 46 4.40(3.29-5.84) 44 4.98(3.70-6.66) 53 10.65(8.09-13.82) <0.0001 
VKA 49 3.43(2.59-4.51) 63 3.28(2.56-4.19) 77 4.16(3.33-5.19) 104 9.48(7.80-11.44) <0.0001 
Relative risk(VKA vs No VKA)   0.54(0.36-0.81)   0.74(0.50-1.08)    0.85(0.58-1.23)   0.89(0.64-1.24)  0.27* 
Major bleeding                
Total 72 3.12(2.48-3.92) 99 3.15(2.58-3.82) 103 3.49(2.87-4.22) 92 5.33(4.34-6.52) 0.002 
No VKA 22 3.08(2.02-4.63) 29 2.75(1.91-3.94) 18 2.04(1.28-3.20) 25 5.32(3.58-7.79) 0.03 
VKA 47 3.36(2.52-4.45) 63 3.45(2.70-4.41) 77 4.30(3.44-5.36) 57 5.11(3.93-6.59) 0.11 
Relative risk(VKA vs No VKA)   1.08(0.65-1.80)   1.26(0.81-1.96)    2.11(1.26-3.53)   0.98(0.61-1.56)  0.15* 
All-cause mortality                
Total 69 2.84(2.24-3.59) 62 1.82(1.42-2.32) 90 2.83(2.30-3.47) 133 7.13(6.01-8.43) <0.0001 
No VKA 33 4.40(3.12-6.14) 24 2.13(1.43-3.16) 29 3.12(2.16-4.45) 44 8.38(6.20-11.16) <0.0001 
VKA 28 1.89(1.30-2.72) 35 1.74(1.25-2.42) 50 2.56(1.94-3.37) 74 6.28(4.99-7.85) <0.0001 
Relative risk(VKA vs No VKA)  0.44(0.27-0.73)  0.80(0.47-1.34)  0.83(0.53-1.32)  0.75(0.52-1.09) 0.24* 
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Table 3. Renal function, renal function worsening and risk of ischaemic stroke/thromboembolism or bleeding events: Results from Cox 
regression analyses 
Ischaemic Stroke/Thromboembolism Hazard Ratio (CI) Bleeding Events Hazard Ratio (CI) 
Univariate analysis  Univariate analysis  
Baseline GFR 0.985(0.981-0.989) Baseline GFR 0.986(0.983-0.990) 
GFR slope (categorical variable)  1.803(1.367-2.378) GFR slope (categorical variable) 1.582(1.245-2.010) 
    
Adjusted for sex and age  Adjusted for sex and age  
Baseline GFR 0.994(0.986-1.001) Baseline GFR 0.990(0.983-0.996) 
GFR slope (categorical variable)  1.825(1.369-2.431) GFR slope (categorical variable) 1.644(1.285-2.104) 
Female gender 1.142(0.885-1.474) Female gender 0.753(0.599-0.947) 
Age per 10-y increase 1.289(1.166-1.414) Age per 10-y increase 1.216(1.113-1.319) 
    
Adjusted for CHA2DS2VASc risk factors  Adjusted for HAS-BLED risk factors  
Baseline GFR 0.996(0.988-1.003) Baseline GFR 0.991(0.985-0.997) 
GFR slope (categorical variable)  1.760(1.314-2.357) GFR slope (categorical variable) 1.578(1.231-2.024) 
Heart failure 1.362(1.055-1.761) Hypertension 1.108(0.895-1.374) 
Hypertension 1.073(0.829-1.389) Liver impairment 0.684(0.095-4.902) 
Age per 10-y increase 1.252(1.126-1.379) Previous stroke 0.934(0.632-1.383) 
Diabetes mellitus 1.186(0.853-1.650) Previous bleeding 1.957(1.410-2.717) 
Previous stroke/thromboembolism 3.584(2.632-4.878) Labile INR 1.543(0.976-2.439) 
Vascular disease 1.258(0.958-1.653) Age per 10-y increase 1.183(1.069-1.309) 
Female gender 1.181(0.909-1.535) Drugs 1.305(1.025-1.664) 
    
Adjusted for CHA2DS2VASc score and antithrombotic therapy  Adjusted for HAS-BLED score and antithrombotic therapy  
Baseline GFR 0.994(0.986-1.002) Baseline GFR 0.991(0.984-0.997) 
GFR slope (categorical variable)  1.573(1.160-2.134) GFR slope (categorical variable)  1.543(1.187-2.004) 
CHA2DS2VASc score 1.336(1.234-1.447) HAS-BLED score 1.265(1.132-1.414) 
Vitamin K antagonist use 1.174(0.868-1.587) Vitamin K antagonist use 1.420(1.087-1.855) 
Antiplatelet use 1.401(1.042-1.880) Antiplatelet use 1.198(0.912-1.570) 
    
*adjusted for Table 1 risk factors and including age as a continuous covariate, the result is only displayed for renal impairment and renal function worsening. 
GFR slope as categorical variable defined as GFR slope in the 4th quartile (<-4.81 ml/min/1.73m
2
/year.  
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